|[May 07, 2014]
Research and Markets: US Companion Diagnostics Market Trends and Insights 2014
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/f9cdnc/us_companion)
has announced the addition of the "US
Companion Diagnostics Market Trends and Insights" report to
A complete companion diagnostic market analysis must include both
developers of targeted drugs and developers of companion diagnostic
tests. This research deliverable discusses important trends in the U.S.
companion diagnostics market including emerging opportunities with novel
drug classes and new clinical markers like circulating tumor cells.
Emerging therapeutic areas beyond oncology for companion diagnostics are
also discussed along with key competitors, rx-cdx partnerships,
regulatory overview, and therapeutic pipelines with companion biomarkers.
There were at least 387 targeted medicines in the pipeline or
currently markete for oncology in 2013. breast cancer, non-small cell
lung cancer (NSCLC), and colorectal cancer have the most targeted drug
Novartis and Roche lead with the most targeted therapies currently
marketed and in development. AstraZeneca, GSK, Pfizer, Sanofi, and BMS
are also focused on targeted therapies marketed with or likely
requiring a companion diagnostics (CDx).
Key market drivers include the unmet need for Cdx in highly
mutationally driven cancers such as NSCLC and melanoma and the growing
interest in novel clinical epigenetic biomarkers and circulating tumor
A promising new drug class, the antibody drug conjugate (ADC (News - Alert)), may
provide new opportunities for CDx. Roche, ImmunoGen, and Seattle
Genetics all have a high number of ADCs in the pipeline and may be
attractive targets for CDx partnering.
Advances such as highly sensitive microfluidic biosensors, single cell
analysis, and deep sequencing of circulating cell-free tumor DNA are
making the concept of the liquid biopsy, or the ability to monitor a
tumor noninvasively, a near-term reality.
Oncology is the primary therapeutic area for CDx development, but
neurological, cardiovascular, gastrointestinal, and muscular diseases
are growing areas for CDx. Within oncology, lung cancer was the most
prominent area where most partnerships between manufacturers were
Key Topics Covered:
Market Overview and Trends
Product Analysis: BRAF, EGFR, KRAS
Companion Biomarker Opportunities in Drug Development
US Regulatory Overview
Therapeutic Pipeline with Companion Biomarker By Pharmaceutical Company
Therapeutic Pipeline with Companion Biomarker By Cancer Type
For more information visit http://www.researchandmarkets.com/research/f9cdnc/us_companion
[ Back To TMCnet.com's Homepage ]